Janux Therapeutics JANX
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001193125-26-337977
- Reports quarterly results (2.02)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
- Schrodinger SDGR public float $1.1B, Jun 30, 2025
- Mannkind MNKD public float $1.1B, Jun 30, 2025
- Mersana Therapeutics MRSN
- Novavax NVAX public float $1.0B, Jun 30, 2025
